<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ayu</journal-id><journal-id journal-id-type="iso-abbrev">Ayu</journal-id><journal-id journal-id-type="publisher-id">Ayu</journal-id><journal-title-group><journal-title>Ayu</journal-title></journal-title-group><issn pub-type="ppub">0974-8520</issn><issn pub-type="epub">0976-9382</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22661846</article-id><article-id pub-id-type="pmc">3361927</article-id><article-id pub-id-type="publisher-id">Ayu-32-512</article-id><article-id pub-id-type="doi">10.4103/0974-8520.96125</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Fundamental approach in the management of <italic>Drava Bahula Amlapitta</italic> with <italic>Bhringaraja (Eclipta alba)</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pol</surname><given-names>Hemant</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>More</surname><given-names>Sharda</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Vyas</surname><given-names>Mahesh Kumar</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vyas</surname><given-names>Hitesh</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ravishankar</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Lecturer, Department of Samhita, Shubhdeep Ayurved Medical College and Hospital, Khandwa Road, Indore, M.P., India</aff><aff id="aff2"><label>2</label>Lecturer, Department of Agada Tantra, Shubhdeep Ayurved Medical College and Hospital, Khandwa Road, Indore, M.P., India</aff><aff id="aff3"><label>3</label>Associate Professor, Department of Basic Principles, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India</aff><aff id="aff4"><label>4</label>Assistant Professor, Department of Basic Principles, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India</aff><aff id="aff5"><label>5</label>Director, Research and Development, SDM Research Centre for Ayurveda and Allied Sciences, Udupi, Karnataka, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Hemant Pol, C/O Mr. Hanumantrao More, &#x02018;Shreevaibhav&#x02019;, Plot no.7, Lokmangal Co-op Hsg.Soc., opp. Hotel Kashmir (Bageecha) Dhaba, Padegaon, Aurangabad - 431005, Maharashtra, India. E-mail: <email xlink:href="drhemantpol@gmail.com">drhemantpol@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2011</year></pub-date><volume>32</volume><issue>4</issue><fpage>512</fpage><lpage>517</lpage><permissions><copyright-statement>Copyright: &#x000a9; AYU (An International Quarterly Journal of Research in Ayurveda)</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The disease <italic>Amlapitta</italic> has been selected for the clinical trials because it presents two type of manifestations depending upon the involvement of <italic>Agni</italic> (<italic>Ushnagunadhikya</italic>) and <italic>Jala</italic> (<italic>Dravagunadhikya</italic>) <italic>Mahabhuta</italic>. The present research work was focused at <italic>Drava Guna</italic>, with an aim to assess the efficacy of a drug with quality of <italic>Ruksha</italic> and <italic>Ushna</italic> predominance like <italic>Bhringaraja</italic> in treating <italic>Amlapitta</italic> with <italic>Pitta Drava Guna Vriddhi</italic>. Randomized open clinical trials were conducted on 22 patients of <italic>Amlapitta</italic> who were screened on the basis of clinical findings and allocated in to two groups. The criteria for selection were the signs and symptoms of <italic>Dravagunadhikya Amlapitta</italic>, irrespective of sex, religion, etc. Group A consisting of 15 cases received the trial drug <italic>Bhringaraja</italic> tablet (4 Tab. two times, 1 tablet=500 mg) and 7 cases in Group B received rice powder tablet as a placebo (4 Tab. two times, 1 tablet=500 mg) for 4 weeks. Special scoring pattern was adopted for the assessment of <italic>Amlapitta</italic>. Routine pathological tests such as blood, urine, stool, etc. were also carried out. In Group A, 55.33% patients showed marked improvement, whereas moderate improvement was observed in 26.67% patients. Complete cure was found in 06.67% of the patients and mild improvement in the chief complaints was observed in 13.33% patients. All the selected symptoms showed statistically significant results (<italic>P</italic>&#x0003c;0.01) except the <italic>Vidbheda</italic> in treated Group A, while in Group B, all symptoms showed statistically insignificant results except the <italic>Utklesha</italic> and <italic>Amlodgara</italic>. Total effect of the therapy showed statistically significant effect of the test drug. These results support the hypothesis</p></abstract><kwd-group><kwd><italic>Amlapitta</italic></kwd><kwd><italic>Bhringaraja</italic></kwd><kwd><italic>Drava</italic></kwd><kwd><italic>Ruksha</italic></kwd><kwd><italic>Ushna Guna</italic></kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p><italic>Amlapitta</italic> is a very common disease in the society and is an abnormal pathological condition of <italic>Pitta</italic>. <italic>Drava Guna</italic> plays an important role in the pathogenesis of <italic>Amlapitta</italic>.[<xref ref-type="bibr" rid="ref1">1</xref>] On the basis of predominant <italic>Rasa</italic> and <italic>Gunatmaka</italic> diet consumed by the patient, one can visualize two types of <italic>Amlapitta</italic> (<italic>Vikalpa Samprapti</italic>) and thus can plan the therapeutic intervention [<xref ref-type="fig" rid="F1">Figure 1</xref>]. If <italic>Nidanas</italic> (diet) are <italic>Amla&#x02013;Lavana&#x02013;Drava&#x02013;Snigdha&#x02013;Ushna</italic> dominant in nature, then <italic>Drava</italic> property of <italic>Pitta</italic> increases, and if <italic>Nidanas</italic> are <italic>Katu</italic>&#x02013;<italic>Ushna</italic>&#x02013;<italic>Ruksha</italic> dominant in nature, <italic>Ushna</italic> and <italic>Ruksha</italic> properties of <italic>Pitta</italic> get increased.[<xref ref-type="bibr" rid="ref2">2</xref>]</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Pathogenesis of <italic>Amlapitta</italic></p></caption><graphic xlink:href="Ayu-32-512-g001"/></fig><p>The present study was carried out to evaluate clinically <italic>Ruksha</italic> and <italic>Ushna</italic> drug, i.e. <italic>Bhringaraja</italic>, in countering the <italic>Drava Bahula Amlapitta</italic>, thereby suggesting a fundamental approach based line of treatment for <italic>Amlapitta</italic>.</p><sec id="sec2-1"><title>Aims and objectives</title><p>This study was carried out with the following aims and objectives:</p><p>
<list list-type="order"><list-item><p>To study the applied concept of <italic>Drava Guna</italic> particularly of <italic>Pitta</italic> in <italic>Amlapitta</italic> patients.</p></list-item><list-item><p>Evaluation of the efficacy of the selected drug <italic>Bhringaraja</italic> on <italic>Drava Guna Vriddhi</italic> of <italic>Pitta</italic> in comparison to placebo.</p></list-item></list>
</p></sec></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><sec id="sec2-2"><title>Criteria of selection of patients</title><p>
<list list-type="order"><list-item><p>For the clinical study, the patients having the symptoms of <italic>Amlapitta</italic> (with <italic>Drava Guna</italic> dominant symptoms.[<xref ref-type="bibr" rid="ref3">3</xref>])</p></list-item><list-item><p>Age: 20&#x02013;60 years.</p></list-item></list>
</p><p>Patients satisfying the above criteria were selected from the OPD/IPD of Department of Basic Principles, I.P.G.T. and R.A., G.A.U., Jamnagar.</p></sec><sec id="sec2-3"><title>Criteria of exclusion of patients</title><p>
<list list-type="order"><list-item><p>Patients below 20 years and above 60 years of age.</p></list-item><list-item><p>Patients having the symptoms of <italic>Amlapitta</italic> (with <italic>Tyaktadravtva</italic> dominant symptoms[<xref ref-type="bibr" rid="ref3">3</xref>]).</p></list-item><list-item><p>Patients suffering from complications of <italic>Amlapitta</italic> like gastritis, duodenal ulcer, etc. and also having any endocrine disorder or chronic complicated disease.</p></list-item></list>
</p></sec><sec id="sec2-4"><title>Grouping</title><p>Patients were divided into two groups.</p><p>
<list list-type="roman-upper"><list-item><p>Group A - Treatment group</p></list-item><list-item><p>Group B - Placebo group</p></list-item></list>
</p></sec><sec id="sec2-5"><title>Drug and posology</title><p>The test drug and placebo used in this study were mentioned in <xref ref-type="table" rid="T1">Table 1</xref> with their details.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Drug, dose, duration</p></caption><graphic xlink:href="Ayu-32-512-g002"/></table-wrap></sec><sec id="sec2-6"><title>Investigations</title><p>Laboratory investigations were carried out before and after treatment to rule out any other pathological conditions as well as to record any specific change brought about by the treatment.</p><p>
<list list-type="bullet"><list-item><p>Routine hematological examinations: Total leukocyte count, differential count, hemoglobin percent, packed cell volume and erythrocyte sedimentation rate before and after treatment.</p></list-item><list-item><p>Biochemical examination: Serum total proteins and A/G ratio, Blood urea level, serum creatinine, serum uric acid, serum alkaline phosphatase, total lipid profile and fasting blood glucose level before and after treatment.</p></list-item></list>
</p></sec><sec id="sec2-7"><title>Study design</title><p>Placebo-controlled randomized clinical trial was done. Informed written consent was taken from the patients before including them in the trial. An elaborative case taking proforma was specially designed for the purpose of incorporating the disease and <italic>Drava Guna</italic> concept.</p><p><italic>Pathyapathya</italic> (wholesome&#x02013;unwholesome diet): Patients were advised to take <italic>Pathyahara</italic> and to correct their dietary habits and avoid <italic>Apathyahara</italic> as per the classical guidelines.</p></sec><sec id="sec2-8"><title>Assessment of therapy</title><p>Relief in signs and symptoms of <italic>Amlapitta</italic> was assessed by B.T. and A.T. gradation of clinical features, on the basis of scoring pattern.</p></sec><sec id="sec2-9"><title>Criteria for overall assessment of therapy</title><p>The overall assessment based on relief from the symptoms is shown in <xref ref-type="table" rid="T2">Table 2</xref>.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Criteria for overall assessment of therapy</p></caption><graphic xlink:href="Ayu-32-512-g003"/></table-wrap></sec><sec id="sec2-10"><title>Statistical analysis</title><p>The information gathered on the basis of observations was subjected to statistical analysis. Chi-square test and Student's paired &#x0201c;<italic>t</italic>&#x0201d; test were carried out for all subjective parameter (symptoms). Student's paired &#x0201c;t&#x0201d; test was applied for the objective parameters like hematological and biochemical investigations. The results were interpreted at <italic>P</italic>&#x0003c;0.05, <italic>P</italic>&#x0003c;0.01 and <italic>P</italic>&#x0003c;0.001 significance levels. Total effect of therapy was calculated with the help of Chi-square test.</p></sec></sec><sec id="sec1-3"><title>Observations, Results and Discussion</title><p>In the present study, 42 patients of <italic>Amlapitta</italic> [<xref ref-type="table" rid="T3">Table 3</xref>] were evaluated. It was found that 42.86% patients were in the age group of 31&#x02013;40 years [<xref ref-type="table" rid="T4">Table 4</xref>], which is <italic>Pitta Dosha</italic> dominance stage of life. This finding correlates with the findings of Iyer Shividya, Prof. R. R. Dwivedi <italic>et al</italic>. (2003) and Santosh Mane, Prof. R. R. Dwivedi <italic>et al</italic>. (2008). At this particular age, strenuous work, traveling, dietetic incompatibilities like <italic>Vishamashana</italic>, ignorance about <italic>Dinacarya</italic>, etc. are the other factors that set a solid foundation for <italic>Pitta</italic> disorders due to vitiation of <italic>Agni</italic>. Maximum (i.e. 69.04%) patients were taking <italic>Snigdha, Ushna, Guru, Drava</italic> diet like oily substance, spicy food which contains Snigdha as well as <italic>Ushna Guna</italic> [<xref ref-type="table" rid="T5">Table 5</xref>]. The symptoms exaggerated in 76.12% patients in relation to oily, spicy diet [<xref ref-type="table" rid="T6">Table 6</xref>]. These observations of the two tables indicate that <italic>Snigdha&#x02013;Ushna Gunatmaka </italic>diet provokes the <italic>Drava Bahula Amlapitta</italic> which is in accordance with <italic>Madhukosha</italic> commentary view that <italic>Snigdha</italic> and <italic>Ushna</italic> are <italic>Hetu</italic> for <italic>Pitta Drava Vriddhi</italic>.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Status of the registered patients of <italic>Amlapitta</italic></p></caption><graphic xlink:href="Ayu-32-512-g004"/></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Age wise distribution of the 42 patients</p></caption><graphic xlink:href="Ayu-32-512-g005"/></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p><italic>Gunatmaka</italic> dominancy in diet of the 42 patients</p></caption><graphic xlink:href="Ayu-32-512-g006"/></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p><italic>Anupashaya</italic> in relation to oily, spicy diet in 42 patients of <italic>Amlapitta</italic></p></caption><graphic xlink:href="Ayu-32-512-g007"/></table-wrap><p>Maximum patients (80.95%) were habituated with improper diet styles like <italic>Samashana, Vishamashana and Viruddhashana</italic> [<xref ref-type="table" rid="T7">Table 7</xref>]. From this point of view, it can be said that for the manifestation of disease <italic>Amlapitta</italic>, all the above factors may be responsible collectively as well as individually. As per <italic>Acharya Sushruta</italic>, these are the most important factors in creating the <italic>Agnimandya</italic>. However, the role of these factors in increasing <italic>Pitta Dravata</italic> is still not clear. It can be inferred that <italic>Samashana, Vishamashana</italic> and <italic>Viruddhashana</italic> which includes <italic>Snigdha</italic> and <italic>Ushna Gunatmaka</italic> diet may be the reason for increase in <italic>Pitta Dravata</italic>.</p><table-wrap id="T7" position="float"><label>Table 7</label><caption><p>Faulty dietary habits like <italic>Samashana, Vishamashana, Viruddhashana</italic></p></caption><graphic xlink:href="Ayu-32-512-g008"/></table-wrap><p>On examining the <italic>Shareera Prakrti</italic>, it was observed that maximum (i.e. 35.72%) patients prone to this disease were of <italic>Kapha&#x02013;Pittaja</italic> and <italic>Kapha&#x02013;Vata Prakriti</italic>. This shows the tendency of <italic>Kapha Pitta</italic> predominance leading to <italic>Dushti</italic> of <italic>Annavahasrotas</italic> and ultimately producing its symptoms earlier than others [<xref ref-type="table" rid="T8">Table 8</xref>]. In <italic>Amlapitta</italic>, <italic>Pitta</italic> is the leading vitiated <italic>Dosha</italic> and <italic>Kapha</italic> is next to <italic>Pitta</italic>. <italic>Kapha</italic> and <italic>Pitta</italic> both have the <italic>Drava Guna</italic>.[<xref ref-type="bibr" rid="ref4">4</xref>] Hence, <italic>Pitta</italic> and <italic>Kapha Prakriti</italic> persons are more prone to the disease, <italic>Amlapitta</italic>, as <italic>Drava Guna</italic> of <italic>Pitta</italic> increases in <italic>Amlapitta</italic>.</p><table-wrap id="T8" position="float"><label>Table 8</label><caption><p><italic>Deha Prakriti</italic> wise distribution of the 42 patients</p></caption><graphic xlink:href="Ayu-32-512-g009"/></table-wrap><p>In this study 88.09% patients were having <italic>Avara Jarana Shakti</italic> [<xref ref-type="table" rid="T9">Table 9</xref>]. <italic>Pachaka Pitta</italic> is responsible for digestion. In normal condition, <italic>Pachaka Pitta</italic> is devoid (i.e. a smaller amount) of <italic>Drava Guna</italic>. If <italic>Drava Guna</italic> of <italic>Pachaka Pitta</italic> increases, then it decreases <italic>Ushna Guna</italic> of <italic>Pachaka Pitta</italic> which is the most essential <italic>Guna</italic> for digestion. In <italic>Amlapitta</italic>, due to increase in <italic>Drava Guna</italic> and decrease in <italic>Ushna Guna</italic> of <italic>Pitta, Avara Jarana Shakti</italic> was observed. This is in accordance with the classical view that if <italic>Drava Guna</italic> of <italic>Pitta</italic> increases, then it hampers digestion by creating <italic>Agnimandyata</italic>.[<xref ref-type="bibr" rid="ref5">5</xref>]</p><table-wrap id="T9" position="float"><label>Table 9</label><caption><p><italic>Jarana Shakti</italic> wise distribution of the 42 patients</p></caption><graphic xlink:href="Ayu-32-512-g010"/></table-wrap><p>Maximum patients (i.e. 57.14%) had been suffering from <italic>Amlapitta</italic> since more than a month [<xref ref-type="table" rid="T10">Table 10</xref>]. This indicates <italic>Chirakari Swabhava</italic> of <italic>Amlapitta</italic>. 83.33% and 9.05% of the patients were taking <italic>Guru Bhojana</italic> and <italic>Viruddhahara</italic>, respectively, while 38.10% of the patients were taking <italic>Atisnigdhahara</italic> [<xref ref-type="table" rid="T11">Table 11</xref>]. This % of <italic>Aharaja Nidanas</italic> [<xref ref-type="table" rid="T11">Table 11</xref>] directly indicates their role in <italic>Amlapitta</italic>. <italic>Annavaha</italic> and <italic>Rasavaha Srotas</italic> involvement was seen in all of the patients (i.e. 100%) [<xref ref-type="table" rid="T12">Table 12</xref>]. This observation supports the classical view of <italic>Kashyapa</italic> which indicate <italic>Rasa Dhatu</italic> as the main <italic>Dushya</italic> in <italic>Amlapitta</italic>.[<xref ref-type="bibr" rid="ref6">6</xref>]</p><table-wrap id="T10" position="float"><label>Table 10</label><caption><p>Distribution of 42 patients according to the duration of the disease</p></caption><graphic xlink:href="Ayu-32-512-g011"/></table-wrap><table-wrap id="T11" position="float"><label>Table 11</label><caption><p><italic>Nidanas</italic> (etiological factors) observed in 42 patients of <italic>Amlapitta</italic></p></caption><graphic xlink:href="Ayu-32-512-g012"/></table-wrap><table-wrap id="T12" position="float"><label>Table 12</label><caption><p>Involvement of <italic>Srotas</italic> in 42 patients of <italic>Amlapitta</italic></p></caption><graphic xlink:href="Ayu-32-512-g013"/></table-wrap><sec id="sec2-11"><title>Percentage of improvement</title><p>In Group A (<italic>Bhringaraja</italic> treated), 100% relief was observed in <italic>Chhardi</italic> symptom. Next to <italic>Chhardi</italic>, maximum 85.71% relief was observed in <italic>Kandu/Kotha</italic>, followed by 83.33% in <italic>Angasada</italic> and 80.56% in <italic>Amlodgara</italic>. <italic>Utklesha</italic> was reduced by 79.31%, while <italic>Klama</italic> and <italic>Avipaka</italic> improved by 78.26% and 76.92%, respectively. 70.97% relief in <italic>Guru Koshthata</italic> and 66.67% in <italic>Aruchi</italic> were observed. Placebo (Group B) drug showed maximum 52.94% improvement in <italic>Amlodgara</italic> and 50% improvement in <italic>Chhardi</italic>. It also showed improvement in <italic>Utklesha</italic> by 42.11% [<xref ref-type="fig" rid="F2">Figure 2</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Percentage wise improvement in Groups A and B</p></caption><graphic xlink:href="Ayu-32-512-g014"/></fig><p>Use of placebo control excludes the psychological and environmental factors affecting the treatment efficacy. Hence, results obtained in Group A are due to the drug efficacy and not due to the effect of psychological and environmental factors.</p></sec><sec id="sec2-12"><title>Results of student's paired &#x0201c;<italic>t</italic>&#x0201d; test</title><p>Statistically highly significant result (<italic>P</italic>&#x0003c;0.01) was obtained in symptoms like <italic>Utklesha, Amlodgara, Avipaka, Guru Koshthata, Aruchi, Angasada, Klama, Kandu</italic> under Group A. Significant result (<italic>P</italic>&#x0003c;0.05) was obtained in Gaurava symptom, while nonsignificant result was obtained in <italic>Vid Bheda</italic> in Group A [<xref ref-type="table" rid="T13">Table 13</xref>]. Statistically nonsignificant result was obtained in symptoms like <italic>Avipaka, Gaurava, Guru Koshthata, Aruchi, Angasada, Klama, Vid Bheda</italic> in Group B, while statistically significant results (<italic>P</italic>&#x0003c;0.05) were observed in <italic>Utklesha, Amlodgara</italic> symptoms [<xref ref-type="table" rid="T14">Table 14</xref>]. This may be due to <italic>Nidana Parivarjana</italic> and <italic>Pathya</italic> followed by patients.</p><table-wrap id="T13" position="float"><label>Table 13</label><caption><p>Effect of <italic>Bhringaraja</italic> on symptoms of <italic>Amlapitta</italic> in Group A (paired &#x0201c;<italic>t</italic>&#x0201d; test applied to symptoms)</p></caption><graphic xlink:href="Ayu-32-512-g015"/></table-wrap><table-wrap id="T14" position="float"><label>Table 14</label><caption><p>Effect of placebo (rice powder tablet) on symptoms of <italic>Amlapitta</italic> in Group B (paired &#x0201c;<italic>t</italic>&#x0201d; test applied to symptoms)</p></caption><graphic xlink:href="Ayu-32-512-g016"/></table-wrap></sec><sec id="sec2-13"><title>Result of Chi-square test on individual symptoms</title><p>This illustrates that test drug <italic>Bhringaraja</italic> is efficacious insignificantly in improving the above individual symptoms [<xref ref-type="table" rid="T15">Table 15</xref>]. Small sample size and variation of symptoms, i.e. all the symptoms not being present in each patient, may be the reason behind the insignificant results obtained with Chi-square test.</p><table-wrap id="T15" position="float"><label>Table 15</label><caption><p>Results obtained on applying Chi-square test on the symptoms of <italic>Amlapitta</italic></p></caption><graphic xlink:href="Ayu-32-512-g017"/></table-wrap></sec><sec id="sec2-14"><title>Result of paired &#x0201c;<italic>t</italic>&#x0201d; test applied to hematological data and biochemical parameters of Group A</title><p>It is evident that the <italic>Bhringaraja</italic> treated group showed statistically significant increase (paired &#x0201c;<italic>t</italic>&#x0201d; test) in four parameters: Hb (gm%) (<italic>P</italic>&#x0003c;0.001), total red blood cell count (TRBC; &#x000d7;10<sup>12</sup>/l), packed cell volume (PCV; %), and serum glutamate oxaloacetate transaminase (SGOT) [<xref ref-type="table" rid="T16">Table 16</xref>].</p><table-wrap id="T16" position="float"><label>Table 16</label><caption><p>Statistically significant observations of Group A</p></caption><graphic xlink:href="Ayu-32-512-g018"/></table-wrap><p>It can be inferred that statistically significant increase in Hb (gm%) (<italic>P</italic>&#x0003c;0.001), TRBC (&#x000d7;10<sup>12</sup>/l), PCV (%), and SGOT cannot be directly correlated with the <italic>Drava Guna</italic> concept. But as all these parameters can be included in <italic>Pitta Varga</italic>, it can be said that <italic>Bhringaraja</italic> has positive correlation with <italic>Pitta</italic>. Increase in these parameters can be taken as increase in <italic>Agnimabhutatmaka</italic> portion of <italic>Pitta</italic>. It is a hypothetical explanation which requires further logics to prove it. As there is no statistically significant increase or decrease in parameters like serum cholesterol, low density lipoprotein (LDL), and Total Leukocyte Count (TLC) which are considered as <italic>Kapha Varga</italic> parameters, it can be said that <italic>Bhringaraja</italic> has not that much effect on <italic>Kapha Varga</italic> parameters. The test drug did not cause abnormal deviation (out of normal physiological limit) in parameters but helped to maintain them within normal limits (e.g. statistically significant increase in SGOT was observed, but it was within normal range).</p></sec><sec id="sec2-15"><title>Overall effect of therapy in percentage</title><p>Moderate to marked (summation of moderate+marked) improvement was observed in more than 80% and 14.29% of patients in groups A and B, respectively, when data were presented in percentage improvement method [<xref ref-type="table" rid="T17">Table 17</xref>]. 80% and 14.29% values distinctly show the efficacy of <italic>Bhringaraja</italic> in contrast to placebo.</p><table-wrap id="T17" position="float"><label>Table 17</label><caption><p>Overall effect of therapy in percentage</p></caption><graphic xlink:href="Ayu-32-512-g019"/></table-wrap></sec><sec id="sec2-18"><title>Overall effect of therapy with Chi-square test</title><p>Group A (<italic>Bhringaraja</italic> administered) showed statistically highly significant effects on chief complaints as compared to placebo [<xref ref-type="table" rid="T18">Table 18</xref>]. This indicates that though nonsignificant results were obtained when the symptoms were looked at separately, <italic>Bhringaraja</italic> showed increased efficacy when the overall effect was considered.</p><table-wrap id="T18" position="float"><label>Table 18</label><caption><p>Total effect of therapy (Chi-square test) wise distribution of 22 patients</p></caption><graphic xlink:href="Ayu-32-512-g020"/></table-wrap></sec><sec id="sec2-19"><title>Probable mode of action of <italic>Bhringaraja</italic> in <italic>Amlapitta</italic></title><p>In <italic>Amlapitta</italic>, <italic>Drava Guna</italic> of <italic>Pitta</italic> gets increased leading to pathogenesis. If <italic>Drava Guna</italic> increases, for reducing it one should use drugs which have opposite properties to that of <italic>Drava Guna</italic> (according to <italic>Samanya-Vishesha Siddhanta</italic>).[<xref ref-type="bibr" rid="ref7">7</xref>] <italic>Bhringaraja</italic>, the selected drug, has opposite properties (like <italic>Ruksha&#x02013;Ushna</italic>)[<xref ref-type="bibr" rid="ref8">8</xref>] to that of <italic>Drava Guna</italic>, by means of which it is able to reduce increased <italic>Drava Guna</italic> and its actions. As per the classical view, <italic>Ruksha Dravya</italic> (like <italic>Bhringaraja</italic>) can reduce <italic>Dravata</italic>.[<xref ref-type="bibr" rid="ref9">9</xref>] <italic>Ushna Virya Dravya</italic> (like <italic>Bhringaraja</italic>) can reduce <italic>Dravata</italic> of <italic>Grahanistha Sama Pitta</italic>.[<xref ref-type="bibr" rid="ref10">10</xref>] <italic>Bhringaraja</italic> has both these properties, i.e. <italic>Ruksha</italic> and <italic>Ushna Virya</italic>. That is why <italic>Bhringaraja</italic> is capable of reducing <italic>Drava Guna</italic> of <italic>Pitta</italic> in <italic>Amlapitta</italic>. <italic>Drava Guna</italic> is a <italic>Jalamahabhuta</italic> property, while <italic>Bhringaraja</italic> is <italic>Agnimahabhuta</italic> dominant drug. Hence, <italic>Bhringaraja</italic> is supposed to decrease the <italic>Drava Guna</italic>, which has been verified clinically on <italic>Drava Bahula Amlapitta</italic> patients. The present research is helpful to study a different aspect of <italic>Amlapitta</italic> with emphasis on <italic>Drava</italic> property of <italic>Pitta Dosha</italic>. The data support the findings of previous research done at Tata Memorial Hospital, which suggest <italic>Jeerna Amlapitta</italic> as the predisposing disease factor responsible for Cancer of esophagus caused by consumption of excess <italic>Amla</italic> (sour), <italic>Lavan</italic> (salty), <italic>Ushna</italic> (hot), <italic>Snigdha</italic> (unctuous) dominant diet. These factors increase the <italic>Drava</italic> property of <italic>Pitta</italic> and may indeed lead to dreadful diseases.</p></sec></sec><sec sec-type="conclusion" id="sec1-4"><title>Conclusion</title><p>The above explanation proves that <italic>Bhringaraja</italic> has efficacy in treating the <italic>Drava Bahula Amlapitta</italic> in comparison to placebo. <italic>Bhringaraja</italic> can give moderate to marked improvement in <italic>Drava Bahula Amlapitta</italic> patients. Statistically significant results observed in Group A (<italic>Bhringaraja</italic>) specify that the applied concept of <italic>Drava Guna</italic> plays an important role in the pathogenesis of disease. Hence, <italic>Bhringaraja</italic> having <italic>Drava</italic> opposite properties, i.e. <italic>Ruksha&#x02013;Ushna</italic>, can be a choice of remedy for the physician while treating diseases of <italic>Pitta Drava Guna Vriddhi</italic> like <italic>Amlapitta</italic>.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors would like to acknowledge the authorities of I.P.G.T. and R.A., Jamnagar, for providing facilities for the study.</p></ack><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><article-title>Astanga Samgraha with the commentary of Indu</article-title><source>Indu commentary on Sutrasthana</source><year>1991</year><volume>1</volume><issue>13/3</issue><publisher-loc>New Delhi</publisher-loc><publisher-name>Central Council for research in Ayurveda and Siddha (CCRAS)</publisher-name><fpage>196</fpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Shastri</surname><given-names>Sudarshana</given-names></name></person-group><article-title>Madhava Nidana of Madhavakara with Madhukosha Sanskrit commentory of Shrivijayarakshita and Shrikanthadatta with Vidyotini Hindi commentory</article-title><source>Shrikanthadatta</source><year>1996</year><volume>55</volume><edition>26th ed</edition><issue>32</issue><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhambha Sanskrit Sansthan</publisher-name><fpage>206</fpage><lpage>7</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dodiya</surname><given-names>AM</given-names></name><name><surname>Dwivedi</surname><given-names>RR</given-names></name></person-group><source>&#x0201c;Annavaha Srotas Ki Vikruti Evam Amlapitta Vyadhi mein Pitta Evam Agni ki Avasthiti&#x0201d;</source><year>1998</year><publisher-loc>Jamnagar</publisher-loc><publisher-name>(B.P.), IPGT and RA, G.A.U.</publisher-name></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Acharya</surname><given-names>Vaidya Jadavaji Trikamji</given-names></name></person-group><article-title>Charaka Samhita &#x02013; Ayurvedadipika Commentary of Chakrapanidatta</article-title><source>Chakrapani on Chikitsasthana</source><year>2006</year><volume>3</volume><edition>Reprint</edition><issue>283</issue><publisher-loc>New Delhi</publisher-loc><publisher-name>Rashtriya Sanskrit Sansthana</publisher-name></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Acharya</surname><given-names>Vaidya Jadavaji Trikamji</given-names></name></person-group><article-title>Charaka Samhita &#x02013; Ayurvedadipika Commentary of Chakrapanidatta</article-title><source>Sutrasthana</source><year>2006</year><volume>6</volume><edition>Reprint</edition><issue>42</issue><publisher-loc>New Delhi</publisher-loc><publisher-name>Rashtriya Sanskrit Sansthana</publisher-name><fpage>48</fpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Sarma</surname><given-names>Pandit Hemaraja</given-names></name></person-group><article-title>Kashyapa Samhita &#x02013; by Vriddha Jivaka, revised by Vatsya</article-title><source>Khilasthana</source><year>2000</year><volume>16</volume><edition>7th ed</edition><issue>11</issue><publisher-loc>Chaukhamba Sanskrit Sansthana</publisher-loc><publisher-name>Varanasi</publisher-name></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Acharya</surname><given-names>Vaidya Jadavaji Trikamji</given-names></name></person-group><article-title>Charaka Samhita &#x02013; Ayurvedadipika Commentary of Chakrapanidatta</article-title><source>Sutrasthana</source><year>2006</year><volume>1</volume><edition>Reprint</edition><issue>44</issue><publisher-loc>New Delhi</publisher-loc><publisher-name>Rashtriya Sanskrit Sansthana</publisher-name><fpage>9</fpage><comment>Sharirasthana 6/9, p 330</comment></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Shasri</surname><given-names>Brahmashankar</given-names><suffix>Shri</suffix></name></person-group><article-title>Bhava Prakasha Samhita -with Hindi commentary</article-title><source>Guduchyadi Varga-240</source><year>2002</year><edition>10th ed</edition><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhambha Sanskrit Sansthan</publisher-name></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Sarma</surname><given-names>Pandit Hemaraja</given-names></name></person-group><article-title>Kashyapa Samhita &#x02013; by Vriddha Jivaka, revised by Vatsya</article-title><source>Khilasthana</source><year>2000</year><volume>6</volume><edition>7th ed</edition><issue>29</issue><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhamba Sanskrit Sansthana</publisher-name></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="book"><article-title>Sharangadhara Samhita &#x02013; by Pandita Sharangadharacharya with commentary Adhamalla's Dipika and Kashirama's Gudhartha-Dipika</article-title><source>Adhamalla on prathamakhand</source><year>2000</year><volume>4</volume><edition>4th ed</edition><issue>11</issue><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhambha Orientalia</publisher-name></element-citation></ref></ref-list></back></article>